Background {#Sec1}
==========

In sub-Saharan Africa (SSA), malnutrition is endemic and affects 12-26% of the populations of Mali and Senegal \[[@CR1]\]. The term 'malnutrition' refers to undernutrition and/or overnutrition. However, in the present study, we focused on malnutrition as a state of undernutrition. Malnutrition results from two major processes, insufficient dietary intake - namely undernutrition - and/or inflammatory activity \[[@CR2]\]; that both compromise immune functions \[[@CR3],[@CR4]\]. In SSA, the HIV epidemic has been surperimposed onto prevalent nutritional deficits. The infection is also a cause of malnutrition through dietary reduction, nutrient malabsorption, inflammation and metabolic disturbances. When coupled, undernutrition and HIV induce a vicious cycle that hastens disease progression and increases mortality \[[@CR5]\]. Despite increased access to HAART, poor nutritional status persists \[[@CR6]\] and continues to be associated with negative health outcomes \[[@CR7]-[@CR9]\].

Low BMI reflects low energy stores and chronic energy deficiency \[[@CR10],[@CR11]\]. Between 19-63% of patients living with HIV/AIDS (PLA) in SSA display a low BMI at HAART initiation \[[@CR9],[@CR12]-[@CR14]\]. Low BMI strongly predicts disease progression, therapeutic failure and mortality \[[@CR12],[@CR14],[@CR15]\]. More importantly, in low and middle income countries (LMIC) weight loss in the first months of treatment is associated with increased side effects \[[@CR16],[@CR17]\], poor treatment outcomes and mortality \[[@CR7],[@CR9],[@CR13],[@CR15]\].

In PLA, anemia is highly frequent, affecting up to 95% of those in advance stages of the disease \[[@CR15],[@CR18]\]. Its etiology is multifactorial, HIV-associated cytokine production and viral activity lead to reduced hematopoiesis \[[@CR19]\]. In addition, the infection aggravates micronutrient deficiencies that cause anemia \[[@CR20]\]. In treated patients, anemia has been associated with excess mortality, poor treatment outcomes \[[@CR18],[@CR21]\] and excess side effects \[[@CR22]\].

In LMIC, up to 55% of PLA suffer from hypoalbuminemia \[[@CR23]-[@CR25]\]. Albumin is a negative acute phase protein (APP) and biological marker of nutritional status \[[@CR11]\]. Its synthesis and decline are closely linked to protein and energy intake adequacy, as well as ongoing inflammation consequent to malnutrition and/or HIV infection \[[@CR26]\]. Due to its correlation with CD4, both pre and post ART initiation, and its association with mortality despite HAART \[[@CR23],[@CR25],[@CR27]\], hypoalbuminemia has been proposed as a marker of disease progression and treatment response in LMIC \[[@CR28]-[@CR30]\]. Furthermore, albumin may influence the pharmacokinetics \[[@CR31],[@CR32]\] and exacerbate the side effects of ART \[[@CR16]\].

Despite a high prevalence of malnutrition in treated PLA in LMIC, few studies have described post HAART nutritional trajectories in these patients. In two different West African contexts, we examined malnutrition amongst individuals in their first year of treatment by investigating the association between nutritional markers at treatment initiation by and examining nutritional trajectories post HAART.

Methods {#Sec2}
=======

Study design and population {#Sec3}
---------------------------

*ATARAO* (*Appuyer le Traitement AntiRétroviral en Afrique de l'Ouest*) was a one-year cohort that aimed at identifying the determinants of therapeutic success in treatment naïve PLA at two hospitals and two community centers in Bamako and Sikasso, Mali. Attending physicians at participating sites consecutively invited all patients who qualified for ART initiation during the recruitment period to join the cohort. Details concerning inclusion criteria are contained in Table [1](#Tab1){ref-type="table"}. Participants were interviewed at baseline (time of HAART initiation) and invited to return every 3 months thereafter. Informed consent was obtained at baseline. A compensation of ≈ 4 US\$ for transportation was given at every interview. This study was approved by Malian *(Health Ministry)* and Canadian *(Montreal University Hospital Centre -- CHUM)* ethics committees.

Detailed methodology of the ANRS 1290/1215 *(Agence Nationale de Recherche sur le Sida)* has been described elsewhere \[[@CR33]\]. Briefly, the ANRS study is a cohort of patients who initiated HAART as part of the Senegalese antiretroviral drug access initiative (ISAARV) in Dakar (Table [1](#Tab1){ref-type="table"}). Its objectives were to assess the clinical and social impact of HAART. Following pre-enrollment and enrollment visits (baseline), patients were invited to return one month later and every 2 months thereafter. The study was approved by the Senegalese national ethics committee. All patients provided informed consent. The authors of the present article were granted access to the ANRS database, but were not implicated in the study. Collaboration between ANRS and ATARAO began once patient follow-up and databases were completed.

Data collection {#Sec4}
---------------

Demographic data were collected at baseline. Every 3 months, BMI was measured by the same staff member (ATARAO) or by the treating physician (ANRS). Blood samples were collected at each trimester for albumin assessment (ATARAO only). Hemoglobin and CD4 values were measured every 6 months in both studies.

Lost to Follow-Up (LTFU) {#Sec5}
------------------------

Participants were considered LFTU if they missed ≥ 2 consecutive visits (ATARAO) or if they could not be contacted for ≥ 6 months (ANRS). Efforts taken to locate patients, determine their vital status and causes of death of ANRS LTFU patients are described elsewhere \[[@CR33]\]. Similar, but less exhaustive methods, were used in ATARAO.

Outcomes and determinants {#Sec6}
-------------------------

*BMI :* Body weight was measured in grams and height was measured to the nearest 0.5 cm using a stadiometer. BMI cutoffs of 18.5 kg/m^2^ and 16 kg/m^2^ were used to identify mild and severely malnourished patients, respectively \[[@CR34]\].

*Albumin:* Albumin was only available in ATARAO*.* Albumin was measured in Canada in frozen plasma samples collected in Mali. Albumin levels were estimated using QuantiChrom™ BCG Albumin Assay Kit (*BioAssay Systems*). Albumin values under 3.5 g/dl and \<2.5 g/dl indicate moderate and severe hypoalbuminemia, respectively \[[@CR35]\].

*Hemoglobin :* Hemoglobin was measured locally by automated hematology analyzer. Because \> 95% of patients were at least mildly anemic, we chose to use a more severe definition of anemia. Consequently, a cutoff value of ≤ 11 g/dl was used. According to World Health Organization (WHO), this cutoff identifies individuals with moderate and severe anemia \[[@CR36]\].

*CD4 :* CD4 cell counts were measured by FACS count (*Flow Cytometry Assay*) (Becton Dickinson) locally. Only CD4 values measured within a month of the interview's date were kept for analyses.

Statistical analyses {#Sec7}
--------------------

Tests for linear trends in proportions were carried out to identify covariables of malnutrition at time of treatment initiation. Mixed linear models were used to examine longitudinal changes in BMI, hemoglobin and albumin. In these equations, the intercept represented the baseline value of the dependent variable and the time coefficient indicated its rate of change in time. A significant quadratic time term indicated the presence of a nonlinear accelerating pattern. The intercepts, linear and quadratic time terms were examined, and treated as random if significant. All models were adjusted for age, sex, time since entry in the cohort, as well as variables found to be associated with the nutritional status at baseline (p \< 0.20). Continuous variables were centered to the mean. Interactions between baseline predictors and time were examined. Model selection was done using the *Bayesian Information Criterion* (BIC). For graphic purposes, identical mixed linear models were generated using non-centered variables. Analyses were performed using SPSS 18.

Missing data {#Sec8}
------------

Patients with less than two data entry (including baseline) were excluded from multivariate analyses. Consequently, between 20-34% were excluded from multilevel analyses because of incomplete BMI, hemoglobin or albumin data in ATARAO. In ANRS, 13% of the original cohort were excluded from multilevel analyses because of incomplete BMI or hemoglobin data.

Results {#Sec9}
=======

Characteristics of patients at baseline {#Sec10}
---------------------------------------

Respectively, 273 and 404 patients from ATARAO and ANRS were initially recruited. Of which, 250 and 372 were retained in analyses (Table [1](#Tab1){ref-type="table"}). During the course of ATARAO, 22 patients died and 82 were LTFU. Deceased ATARAO patients had significantly lower hemoglobin, albumin and CD4 counts at baseline compared to those who survived. Participants LTFU had a lower BMI at baseline compared to those retained. In ANRS, 45 patients died but very few patients were LTFU (n = 7), hence LTFU were not characterized. Deceased ANRS participants had lower BMI, hemoglobin and CD4 in comparison to survivors *(data not shown)*.

###### 

**Studies characteristics**

                                                             **ATARAO**                                                                                              **ANRS 1215/1290**
  ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------
  *\# patients recruited/\# patients retained in analyses*   273/250                                                                                                 404/372
  *Inclusion criteria (cohort)*                              •≥16 years old                                                                                          •HIV-1 infected
  •Naive to ART                                              •15 years old                                                                                           
  •Qualified for HAART                                       •Non-pregnant                                                                                           
  •Reside close to one of the study center                   •Qualified for HAART                                                                                    
  *Exclusion criteria (analyses)*                            •Pregnancy                                                                                              •Non naive to ART
  •HIV-2 infection or co-infection                                                                                                                                   
  *Start/end date of recruitment*                            June 2007/January 2008                                                                                  August 1998/April 2002
  *Length of FU*                                             1 year                                                                                                  Up to 107 months
  *\# LTFU(%)/\# dead (%)*                                   82 (30%)/22 (8%)                                                                                        7 (2%)/45(11%)
  *First line regimen*                                       2 nucleoside reverse transcriptase inhibitors (NRTI) + 1 non-NRTI (NNRTI) (\>84% received *Triomune)*   2 NRTIs + 1 NNRTI or one protease inhibitor (41.8%), 4.4% received 2 NRTIs alone before May 2000 \[[@CR33]\], 30% received zidovudine
  *Nutrition support*                                        Daily free meals and cooking classes, available to all patients, offered at 1 center.                   None

In both cohorts, baseline malnutrition was frequent, irrespective of the indicator analyzed (Table [2](#Tab2){ref-type="table"}). Median BMI was 19.6 kg/m^2^ (IQR: 17.7-22.4) in ATARAO, and 20.0 kg/m^2^ (18.0-22.3) in the ANRS. In both cohorts, a vast proportion of patients suffered from anemia (median Hb = 10.5~(ATARAO)~, 10.6~(ANRS)~; IQR = 9.4-11.8~(ATARAO)~, 9.5-11.9~(ANRS)~). In ATARAO, median albumin level at baseline was 3.67 (IQR = 2.67-5.10). Finally, median CD4 counts were 163 (IQR = 54--275) in ATARAO and 120 (IQR = 46--214) cells/mm^3^ in ANRS. At treatment initiation, mean BMI, hemoglobin and CD4 counts did not differ significantly across studies.

Covariates of malnutrition {#Sec11}
--------------------------

At baseline, the proportion of individuals with a low BMI augmented with worsening of anemia or hypoalbuminemia statuses (Table [3](#Tab3){ref-type="table"}). A similar tendency was observed across strata of CD4 counts. Only in Senegal, women were significantly more anemic than men at baseline. In both cohorts, there was an increasingly greater proportion of patients with hemoglobin levels ≤ 11 g/dl with decreasing BMI and CD4 counts. Albumin levels \< 3.5 g/dl were increasingly more frequent across higher grades of anemia and lower CD4 counts. Although not significant, hypoalbuminemia appeared to be more frequent among those with lower BMI.

Pooled data from both cohorts were used to examine associations between nutritional markers (BMI, hemoglobin, and albumin) according to CD4 counts (CD4 \< 200, CD4 ≥ 200). In spite of stratification, associations between BMI and hemoglobin maintained their significance *(data not shown)*.

Baseline determinants of nutritional trajectories {#Sec12}
-------------------------------------------------

Table [4](#Tab4){ref-type="table"} presents the associations between baseline nutritional and immunological characteristics, and variations in nutritional trajectories across time for both studies. Figure [1](#Fig1){ref-type="fig"} illustrates BMI, hemoglobin and albumin sex-specific trajectories during follow up.

In model 1, random and fixed linear and quadratic time terms were significant in both cohorts (p \< 0.001) indicating a positive change in BMI in the first months followed by a later decline. Women initiated treatment with higher BMI, but gained in a similar fashion to men over time (Figure [1](#Fig1){ref-type="fig"}). In ATARAO, BMI trajectories reached a plateau after 9 months of treatment with a slight decrease at the end of the year. In ANRS, men and women gained less over time and plateaued at around the same time as in ATARAO. At 6 months, 12% and 17% of Malian and Senegalese patients, respectively, continued to have a BMI \<18.5 kg/m^2^. While this proportion decreased to 6.9% at 12 months in Mali, as many Senegalese (17.8%) were malnourished according to their BMI status at the end of the first year of treatment. Most of these (\>70%) had a BMI \<18.5 kg/m^2^ at HAART initiation in both populations (*data not shown*).

###### 

**Baseline characteristics of patients from the ATARAO and ANRS 1290 cohorts**

                          **ATARAO (n = 250)**   **ANRS (n = 372)**                
  ----------------------- ---------------------- -------------------- ----- ------ -------------
  **Sex**                                                                          **\<0.001**
  *Men*                   74                     29.6                 168   45.2   
  *Women*                 176                    70.4                 204   54.8   
  **Age** (years)                                                                  **0.001**
  *\<25*                  27                     10.8                 19    5.1    
  *25-29*                 45                     18.0                 57    15.3   
  *30-39*                 105                    42.0                 146   39.2   
  *≥40*                   73                     29.2                 150   40.3   
  **BMI** (kg/m^2^)                                                                0.307
  *≤16*                   32                     12.8                 31    9.7    
  *16-18.5*               58                     23.2                 68    21.3   
  *18.5-25*               140                    56.0                 191   59.7   
  ≥25                     20                     8.0                  30    9.4    
  **Hemoglobin** (g/dl)                                                            0.665
  \<8.0                   21                     8.5                  26    7.0    
  8-9.5                   43                     17.5                 66    17.9   
  9.5-11.0                79                     32.1                 114   30.9   
  \>11.0                  103                    41.9                 163   44.2   
  **Albumin** (g/dl)                                                               \-
  *≤2.5*                  52                     21.7                 \-    \-     
  *2.5-3.5*               63                     26.3                 \-    \-     
  *3.5-4.2*               38                     15.8                 \-    \-     
  \>4.2                   87                     36.3                 \-    \-     
  **CD4** (cells/mm^3^)                                                            0.116
  *\<100*                 93                     37.2                 154   42.3   
  *100-200*               53                     21.2                 105   28.8   
  *200-350*               86                     34.4                 86    23.6   
  *\>350*                 18                     7.2                  19    5.2    

\*p value comparing means between cohorts.

Bold data = p \< 0.05.

There was an initial improvement in hemoglobin levels subsequent to treatment initiation, followed by a decline in later months (model 2, Figure [1](#Fig1){ref-type="fig"}). Respectively, 31 and 33% of patients were anemic at 6 months in ATARAO and ANRS, while 26 and 29% continued to be anemic at 12 months. Women had lower hemoglobin levels in both cohorts. Furthermore, Senegalese women showed a greater decline over time than men. Although age, albumin and CD4 in ATARAO were not significant, model adjustment was improved by keeping these variables (Table [4](#Tab4){ref-type="table"}).

In ATARAO, albumin increased similarly for both men and women during the first 9 months of treatment, but declined in the course of the last trimester (model 3, Figure [1](#Fig1){ref-type="fig"}). Respectively, 6% and 11% of patients had albumin level \< 3.5 g/dl at 6 and 12 months (*data not shown*). Sex was excluded as it failed to improve the fit of the model.

###### 

**Factors associated with malnutrition at baseline: bivariate associations**

                      **BMI \< 18.5**   **Anemia**   **HypoALB** ^¥^                                           
  ------------------- ----------------- ------------ ----------------- ------ ------ ----------- ------ ------ -----------
  ATARAO                                                                                                       
  Sex                                                0.788                           0.055                     0.773
  *Men*               74                35.1                           74     50.0               71     46.5   
  *Women*             176               36.9         176               63.1          169         48.5          
  Age (years)                                        0.186                           0.531                     0.151
  *\<25*              27                51.9                           27     70.4               25     60.0   
  *25-29*             45                37.8                           45     62.2               45     53.3   
  *30-39*             105               32.4                           105    52.4               99     44.4   
  *≥40*               73                36.4                           73     63.0               71     45.1   
  BMI (kg/m^2^)                                                                      **0.000**                 0.052
  *≤16*               \-                                               32     75.0               31     53.3   
  *16-18.5*           \-                                               58     81.0               55     62.5   
  *18.5-25*           \-                                               140    50.0               142    44.8   
  ≥25                                                                  20     35.0               22     41.2   
  Albumin (g/dl)                                     **0.015**                       **0.007**                 
  *≤2.5*              52                50.0                           52     71.2   \-                        
  *2.5-3.5*           63                35.5                           63     65.1   \-                        
  3.5-4.2             38                31.6                           38     60.5   \-                        
  *\>4.2*             87                28.7                           87     49.4               \-            
  Hemoglobin (g/dl)                                  **0.000**                                                 **0.024**
  *\<8*               21                61.9                           \-                        97     40.2   
  *8-9.5*             43                53.5                           \-                        77     49.4   
  *9.5-11*            79                41.8                           \-                        41     61.0   
  *\>11*              103               21.4                           \-                        21     57.1   
  CD4 (cells/mm^3^)                                  **0.001**                       **0.002**                 **0.009**
  *\<100*             93                47.3                           93     66.7               90     55.6   
  *100-200*           53                28.3                           53     66.0               50     50.0   
  *200-350*           86                25.6                           86     54.7               82     45.1   
  *\>350*             18                16.7                           18     22.2               18     16.7   
  ANRS                                                                                                         
  Sex                                                0.132                           **0.000**                 
  *Men*               148               35.1                           166    47.6               \-            
  *Women*             172               27.3                           203    68.0               \-            
  Age (years)                                        0.777                           0.305                     
  *\<25*              15                26.7                           19     68.4               \-            
  *25-29*             50                30.0                           56     64.3               \-            
  *30-39*             120               35.0                           145    56.6               \-            
  *≥40*               135               28.1                           149    57.7               \-            
  BMI (kg/m^2^)                                                                      **0.002**                 
  *≤16*               \-                                               31     80.6               \-            
  *16-18.5*           \-                                               67     68.7               \-            
  *18.5-25*           \-                                               189    53.4               \-            
  ≥25                 \-                                               30     53.3               \-            
  Hemoglobin (g/dl)                                  **0.013**                                                 
  *\<8*               23                43.5                           \-                        \-            
  *8-9.5*             61                36.1                           \-                        \-            
  *9.5-11*            99                35.4                           \-                        \-            
  *\>11*              137               23.1                           \-                        \-            
  CD4 (cells/mm^3^)                                  **0.017**                       **0.000**                 
  *\<100*             136               38.2                           154    69.5               \-            
  *100-200*           88                30.7                           104    55.8               \-            
  *200-350*           71                18.3                           85     45.9               \-            
  *\>350*             19                31.6                           19     42.1               \-            

\* Obtained by trend test (linear by linear association chi^2^ statistic).

¥ Albumin (ALB) was only available in ATARAO.

Bold data = p \< 0.05.

Discussion {#Sec13}
==========

Our study was the first to investigate BMI, hemoglobin and albumin in a cross-sectional and longitudinal manner among populations initiating HAART. In both ATARO and ANRS, an important proportion of patients were malnourished at time of treatment initiation, irrespective of the nutritional marker investigated. These results coincides with observations from other African studies \[[@CR7],[@CR15],[@CR24],[@CR25],[@CR37]\]. As in these previous reports, significant covariation between nutritional markers was observed at baseline, which could suggests that these indicators capture a similar process.

As demonstrated here, independent of baseline nutritional status, HAART contributed to early improvement in BMI, hemoglobin and albumin statuses in most patients. Both in ATARAO and ANRS studies, the proportion of patients with a low BMI, anemia or hypoalbuminemia decreased during the first year of treatment -- especially in the first 6 months. However, trajectories plateaued during the second part of the year. Consequently, low BMI remained prevalent. Twelve months after initiating HAART, 7% of patients continued to have a BMI \< 18.5 kg/m^2^ in ATARAO and 18% in ANRS -- 70% of whom had a low BMI at treatment initiation. BMI trajectories resembled those observed in studies from similar context. As observed elsewhere, most patients gained weight before reaching a plateau at 9 \[[@CR38]\] or 12 months post HAART \[[@CR39]\]. Typically, those who initiated treatment with the lowest BMI gain the most weight. However, despite this increase, it has been shown that these patients failed to catch up to those well-nourished at HAART initiation.

Similarly, in both ATARAO and ANRS, about a third of patients continued to be anemic at 6 and 12 months despite initial improvements; most of whom were already identified as such at baseline *(data not shown)*. These hemoglobin gains were less impressive in terms of absolute increase and sustainability compared to previous reports \[[@CR37]\]. Interaction between sex and hemoglobin trajectories in ANRS could be explained by the use of zidovudine, which was not used in ATARAO \[[@CR40]\].

Finally, after 6 months of treatment, less than 6% of participants were hypoalbuminemic compared to 48% at baseline. These early improvements in albumin levels could indicate lessening of the HIV associated inflammatory processes in response to HAART's action on viral replication \[[@CR41]\]. However, by the end of the year, initial gains subsided and an increasing proportion of our patients (11%) displayed hypoalbuminemia. This sudden drop could be attributable to various causes including persisting chronic malnutrition \[[@CR31],[@CR32]\]. Hence, patients with normal albumin would better benefit from ART. No other study has modeled albumin trajectories post HAART.

Our results indicate that malnutrition either subsists or appears despite HAART. Weight or BMI loss, but also the absence of weight gain in the months following treatment initiation, are risk factors of mortality \[[@CR8]\], especially among those initiating treatment with a low BMI \[[@CR7],[@CR13]\]. In PLA, a deficient nutritional status could result from inadequate nutrient intake, but also from ongoing inflammatory process (either secondary to the infection or malnutrition itself). Many questions have been raised concerning the validity and use of nutritional markers in HIV patients \[[@CR42],[@CR43]\]. Identifying the exact etiology of subnormal nutritional markers in HIV+ individuals from LMIC is a difficult task as malnutrition is surperimposed onto other ubiquitous inflammatory triggers such as malaria, parasites, and tuberculosis leading to excess immune activation in PLA in these settings \[[@CR27]\]. However, we suspect that, for most patients, food insecurity and access to nutritious food varied little during follow up and consequently contributed to maintaining malnutrition amongst treated patients.Figure 1Nutritional trajectories according to average baseline values.

Associations between nutritional markers persisted even after stratification by baseline CD4 counts, contrary to previous reports from LMIC. These earlier studies observed a positive significant covariation between BMI and hemoglobin/albumin at low, but not at high CD4 counts, suggesting that they were markers of more advanced disease and inflammation, rather than a nutritional marker \[[@CR42]\].

###### 

**Associations between nutritional and immune markers at baseline and nutritional trajectory over 12 months follow-up**

                 **Model 1. BMI**          **Model 2. Hemoglobin**   **Model 3. Albumin**                                               
  -------------- ------------------------- ------------------------- ------------------------- --------------- ------------------------ ---------
  Constant       19.1 (18.2; 20.0)         \< .001                   11.2 (10.8; 11.6)         \<.001          3.85 (3.66; 4.05)        \< .001
  Sex (Female)   1.41 (0.40; 2.42)         .006                      \- 0.95 (−1.44;-0.47)     \<.001          *-*                      
  Age\*          0.06 (0.01 ; 0.12)        .012                      0.003 (−0.022; 0.027)     .826            −0.007 (−0.026; 0.012)   .466
  BMI\*          *-*                                                 0.13 (0.08;0.20)          \< .001         0.08 (0.03; 0.13)        .002
  Albumin\*      0.36 (0.10; 0.61)         .007                      0.12 (−0.007;0.242)       .064            *-*                      
  Hemoglobin\*   0.46 (0.23,0.69)          \< .001                   *-*                                       0.09 (0.001; 0.196)      .048
  CD4\*          0.003 (0.000;0.007)       .021                      0.001 (−0.000;0.003)      .077            0.001 (−0.000; 0.003)    .096
  **ANRS**       ***Estimate (95% CI)***   ***p value***             ***Estimate (95% CI)***   ***p value***                            
  Constant       19.4 (19.0; 19.9)         \< .001                   11.1 (10.8; 11.4)         \< .001         \-                       
  Sex (Female)   1.48 (0.84; 2.11)         \< .001                   −0.82 (−1.21; −0.43)      \< .001         \-                       
  Age\*          0.05 (0.02; 0.09)         .002                      *0.01 (−0.00; 0,03)*      .121            \-                       
  BMI\*          *-*                                                 *0.08 (0.04;0.12)*        \< .001         \-                       
  Hemoglobin\*   0.46 (0.31; 0.62)         \< .000                   *-*                                       \-                       
  CD4\*          0.004 (0.002; 006)        .001                      *0.002 (0,000; 0,003)*    .007            \-                       
  Sex x time     *-*                                                 -.0.07(−0.11; −0.02)      .003            \-                       

Only fixed coefficients are present here.

\*Centered to the mean.

Finally, immunodeficiency appeared to be strongly linked to malnutrition at time of treatment initiation, but the predictive value of baseline CD4 was somewhat weaker in multilevel modeling. Many conflicting reports have emerged concerning the interrelation between immunity and malnutrition in HAART treated patients. Some have found positive links \[[@CR29],[@CR30],[@CR44]\]; others have failed to uncover significant associations \[[@CR25],[@CR42],[@CR45]\]. A possible explanation could be that the association between nutritional status and CD4 counts is influenced by the range of CD4 values \[[@CR44]\] or prevalence of malnutrition. In our study, associations among nutritional markers were similar in those with relatively high (≥200) and with low (\<200) CD4 counts. This observation would argue for the independence of the association between nutritional markers at this low end of the CD4 distribution, suggesting a phenomenon that could not be explained by immunosuppression.

Limitations {#Sec14}
-----------

The main limitations of our study were 1) attrition, and 2) missing data, especially biochemical and hematological. Both cohorts suffered from high mortality and LTFU rates. Nonetheless, these rates approximated that observed elsewhere in LMIC \[[@CR46],[@CR47]\]. In these contexts, LTFU is frequent \[[@CR48]\] and linked to non-documented mortality, migration, stigma, and side effects \[[@CR48]\]. In both studies, attrition was strongly associated with malnutrition and immunosuppression. This phenomenon led to an under-representation of malnourished individuals and probable misrepresentation of nutritional trajectories. Hence, our models are possibly optimistic evaluations of the true nutritional trajectories in treated PLA.

Conclusion {#Sec15}
==========

As observed in ATARAO and ANRS, low BMI, anemia or hypoalbuminemia, at time of initiation or in the first year of therapy, have an impact on the health of patients as they put them at risk of persistent malnutrition, LTFU and mortality. Independently of treatment and level of immunosuppression, malnutrition persisted among patients receiving HAART. Antiretrovirals alone may not be sufficient to overcome malnutrition and death in treated PLA. Pharmaceutical interventions should be complemented, if not preceded, with programs to fight undernutrition and food insecurity.
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